Company Overview and News
The Semiconductor – Communications Industry includes companies that provide analog, mixed-signal and digital signal processing integrated circuits to consumer, mobile, desktop, automotive, industrial, IoT, wearable devices and other markets.
DSPG CY NPTN
2018-08-18 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
FOCS PDD LGCYP LGCYO QEP TJX EL AVGO ABBV FTNT KLXI CORR ESES SDPI TENB LNR RRS WPX FSBW ESTE NPTN ERF BABA SDCJF PAY MSFT GPS MPOYQ HRS FL MLM BLCN MOS SEA CLPS LB CLB ROSEU DBX CF CRDAF KSS CRDAD CI SSI JAG ROSE SNDE DAVA SJM UNT HUM EOG BHI RGRYY MU LGCY SBUX MNK WRD LOW JKS TOL LONE ERF CLB FTK AMAT CRD KEG KEGX SOXX STT FSWB WLL AQST SM LBRT BV LLEX ADIL NBR RGRLF CMG RRC INTU HIMX BJRI EDUC BE MPO ABBV BA ESRX ECR JG NDLS WPXP MTB RRL VMW ALRM LQDA RMBS ECA CANG ICD OPRA IBM WISA CDEV JGPK LYB COG ECA SPDI SBOW PHX TGT NTR BRY HPQ URBN TELL
2018-07-03 seekingalpha - 1
The Thin-film equipment division designs, manufacture, and services capital equipment that deposit thin films on the surface to produce magnetic disks for hard disk drives, centralized storage for cloud computing. Additionally, other applications and a key to material near-term growth include touch panels such as mobile phones' front and back, notebooks, smartwatch, tablets, and automotive monitors.
CYBE ASYS AXTI XCRA ACLS CLFD NPTN KOPN NANO IVAC PRCP COHU ESIO
2018-06-11 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Shares of NeoPhotonics (NYSE:NPTN) have pretty much been rangebound for the better part of the past six months. Bulls would believe that the company is poised to grow substantially once client spending on 100G-plus products gains momentum. That may very well be the case indeed, but there's a major risk factor that the broad swath of long-side investors is probably unaware of that can really hurt NeoPhotonics' business - its massive revenue exposure to Huawei.
OCLR ACIA ZTCOY NPTN
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to NPTN / NeoPhotonics Corp, on message board site Silicon Investor.
|Neophotonics(NPTN)||Neophotonics(NPTN)||Neophotonics(NPTN)||The Neptune Society (NPTN)||The Neptune Society (NPTN)||The Neptune Society (NPTN)|
as of ET